Kamada KMDA 深 沪
已收盘 08-21 16:00:00 美东时间
8.24
+0.220
+2.74%
华盛通- 最 高8.25
- 今 开8.02
- 成交量 11.29万股
- 最 低 8.02
- 昨 收 8.02
- 总市值 4.75亿
- 52周最高 9.10
- 市盈率 静 23.80
- 换手率 0.20%
- 52周最低 6.25
- 委 比 39.15%
- 总股本 5769.43万
- 历史最高 17.50
- 量 比 0.41
- 振 幅 2.87%
- 历史最低 2.57
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kamada declares $0.17 dividend
Kamada (KMDA) declares $0.17/share dividend. Payable Sept. 17; for shareholders of record Aug. 27; ex-div Aug. 27. See KMDA Dividend Scorecard, Yield Chart, & Dividend Growth. More on Kamada Kamada Lt...
08-17 20:29
Kamada CFO Chaime Orlev to step down
Kamada (KMDA) said CFO Chaime Orlev will step down from his role effective December 31, 2026, to pursue other opportunities. The company has begun searching for his successor. Orlev, who has served as...
08-12 19:27
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
08-12 19:07
Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $54.921 million which bea...
08-12 19:07
Kamada Announces Planned Transition of Chief Financial Officer
Kamada Ltd. announced that Chief Financial Officer Chaime Orlev will transition out of his role effective December 31, 2026, to pursue other opportunities. Kamada is currently searching for a successor, and Orlev will provide transitional support to the new CFO. CEO Amir London thanked Orlev for his nine years of leadership and contributions to the company's growth. Orlev expressed gratitude for his tenure and confidence in Kamada's continued gro...
08-12 11:00
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Kamada Ltd. will release its second-quarter and first-half 2026 financial results on August 12, 2026, before U.S. markets open. Management will host a conference call at 8:30am ET to discuss the results and answer questions. The call can be accessed via phone or webcast. Kamada, a global biopharmaceutical company, focuses on rare and serious conditions, with a portfolio of six FDA-approved plasma-derived products and a strategy centered on organi...
08-05 11:00
Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today highlighted results of an Investigator-Initiated Study recently presented...
07-13 19:19
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Kamada Ltd. highlighted results from a study presented at the 2026 ISHLT annual meeting, showing that CYTOGAM, the company's CMV immune globulin, is associated with improved clinical outcomes in high-risk lung transplant recipients. The study demonstrated that patients receiving CMVIG prophylaxis experienced better outcomes compared to those who did not, with reduced innate immune cell activation and less lung injury. These findings support the p...
07-13 11:00
Kamada Announces FDA Approval Of New In-House Rapid Fluorescent Focus Inhibition Test Laboratory
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field,
06-01 19:05
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Kamada Ltd. announced FDA approval of its new in-house RFFIT laboratory, a gold standard test for rabies-neutralizing antibodies. Located in Israel, the lab enhances the company's capabilities for KEDRAB® and KAMRAB® manufacturing. The lab, also approved by Health Canada and the Israeli Ministry of Health, supports operational efficiency and innovation. Kamada's 2025 sales of these products exceeded $70 million, highlighting their importance in t...
06-01 11:00
